BKM120

Name: BKM120
SKU: B4248
Availability: InStock

Product ID B4248

Cas No. 944396-07-0

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for brain metastases of HER2+ breast cancer and other solid tumors. BKM120 exhibits anticancer chemotherapeutic and anti-metastatic activities, inducing G2/M phase cell cycle arrest, polyploidy, and apoptosis in glioblastoma cells. Additionally, BKM120 decreases levels of Mcl-1 and enhances TRAIL-dependent apoptosis in lung cancer cells. BKM120 also binds tubulin, inhibiting microtubule polymerization. This compound prevents invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.	944396-07-0
Purity	≥98%
Formula	C₁₈H₂₁F₃N₆O₂
Formula Wt.	410.39
IUPAC Name	5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
Synonym	Buparlisib, NVP-BKM120
Solubility	DMSO 82 mg/mL (199.8 mM) Ethanol 2 mg/mL (4.87 mM) Water Insoluble
Appearance	White to off white powder

Shipping and Storage

Store Temp	4°C
Ship Temp	Ambient

Downloads

MSDS	B4248 MSDS PDF
Info Sheet	B4248 Info Sheet PDF
Brochures	PI3K-Akt-mTORC Pathway Booklet

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Wachsberger PR, Lawrence YR, Liu Y, et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Feb 6. [Epub ahead of print]. PMID: 24500492.

Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Jan 10. [Epub ahead of print]. PMID: 24405565.

Ren H, Zhao L, Li Y, et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 2013 Sep 28;338(2):229-38. PMID: 23562472.

Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Comments
This field is for validation purposes and should be left unchanged.

BKM120

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

Levetiracetam

Sterigmatocystin

4-(Methylsulfinyl) butylamine

5-Aza-2′-deoxycytidine

Oxytetracycline

Cytochalasin E

Florfenicol

Levitide

Tosufloxacin Tosylate

Sulfadimethoxine

Benfotiamine

Mechlorethamine Hydrochloride

Chlorogenic Acid (from Lonicera)

M40

Ziconotide

Substance P

11,12-Dimethoxydihydrokawain

Palmatine Chloride Hydrate

S-(+)-Methoprene

Pazufloxacin Methanesulfonate

Footer